These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34469831)

  • 41. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
    Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
    Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using Chemical Epigenetics to Target Cancer.
    Wimalasena VK; Wang T; Sigua LH; Durbin AD; Qi J
    Mol Cell; 2020 Jun; 78(6):1086-1095. PubMed ID: 32407673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy.
    Voutsadakis IA
    J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
    Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
    SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
    Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
    Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
    Baker IM; Smalley JP; Sabat KA; Hodgkinson JT; Cowley SM
    Biochemistry; 2023 Feb; 62(3):645-656. PubMed ID: 35948047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
    Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
    Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.
    Rahman S; Sowa ME; Ottinger M; Smith JA; Shi Y; Harper JW; Howley PM
    Mol Cell Biol; 2011 Jul; 31(13):2641-52. PubMed ID: 21555454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
    Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
    Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
    McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
    ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteolysis-targeting chimera molecules targeting SHP2.
    Yu D; Zheng M; Liu Y; Chen L; Li H
    Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3.
    Wang C; Wang Q; Xu X; Xie B; Zhao Y; Li N; Cao X
    J Exp Med; 2017 Dec; 214(12):3597-3610. PubMed ID: 29101251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
    French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
    Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.
    Kounde CS; Shchepinova MM; Saunders CN; Muelbaier M; Rackham MD; Harling JD; Tate EW
    Chem Commun (Camb); 2020 May; 56(41):5532-5535. PubMed ID: 32297626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
    Wang M; Lu J; Wang M; Yang CY; Wang S
    J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.